論文発表(業績)
No | Title(論文) | Author (著者) |
Journal(掲載誌)
Vol&Page(号数、ページ数) / Year (掲載年) |
Pub Med ID |
---|---|---|---|---|
85 | Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens | Kamigaki T, Takimoto R, Okada S, Ibe H, Oguma E , Goto S | Anticancer Research
44(9):3713-3724 / 2024 |
39197920 |
84 | A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer | Yu Okazawa, Takashi Kamigak, Kiichi Sugimoto, Takeshi Yamada, Yoichiro Yoshida, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Takuma Iwai, Akihisa Matsuda, Teppei Yamada, Suguru Hasegawa, Shigenori Goto, Rishu Takimoto, Kazuhiro Sakamoto | Oncology Letters
January 15, 2024 101 |
38298433 |
83 | Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma | Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, Takimoto R, Asai J, Kakinoki K, Urabe T, Tomita K, Kaneko S. | International Journal of Cancer
Sep 7. doi: 10.1002/ijc.34716. Online ahead of print. / 2023 |
37676069 |
82 | Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG) | Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino K, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda S, Okamoto M, Yoshimoto Y, Okada S, Ibe H,Oguma E, Goto S for theCITEG. | Cytotherapy
Available online 22 July 2023 / 2023 |
37486281 |
81 | Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors | Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E , Goto S | Anticancer Research
42: 4179-4187 / 2022 |
35896218 |
80 | Long-term, 25-year Survival Following Surgery and Immune Cell Therapy Combined with Chemotherapy for HER2-Positive Metastatic Breast Cancer: A Case Report | Shindo G, Endo T, Miyamoto Y, Onda M, Kimura M, Takimoto R,Ibe H, Goto S. | British Journal of Cancer Research
4(2): 491 – 495 / 2021 |
|
79 | Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy | Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E , Goto S | Anticancer Research
41:4133-4141 / 2021 |
34281884 |
78 | Esophageal cancer responsive to the combination of immune cell therapy and low‑dose nivolumab: two case reports | Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E , Goto S | Journal of Medical Case Reports
15, Article number: 191 / 2021 |
33827668 |
77 | Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. | Kumai T, Mizukoshi E, Hashiba T, Nakagawa H, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Tomita K, Kaneko S | CYTOTHERAPY
Feb;23(2):137-145 / 2020 |
32907781 |
76 | Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy | Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N,Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naitoh K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S. | Anticancer Research
40: 4763-4771 / 2020 |
32727803 |
75 | Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix | Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, Yasumoto K, Okada S, Takizawa K, Yokomichi N, Suzuki N, Takeda S. | Anticancer Research
40: 4741-4748 / 2020 |
32727800 |
74 | Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy A Retrospective Study | Takimoto R, Kamigaki T, Okada S, HIROSHI Ibe H, Oguma E, Naitoh K, Makita K, Yasumoto K, Goto S. | Anticancer Research
40: 4729-4740 / 2020 |
32727799 |
73 | Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer | Miura M, Mizukoshi E, Hashiba T, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Kaneko S. | Cancer Med
9(14):4907-4917 / 2020 |
32529780 |
72 | Identification of prognostic factors for gdT cell immunotherapy in patients with solid tumor | Takimoto R, Miyashita T,Mizukoshi E, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Yasumoto K, Makita K, Tomita K, Goto S. | CYTOTHERAPY
Jun;22(6):329-336 / 2020 |
32303429 |
71 | Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study | Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S. | Anticancer Research
39: 4525-4532 / 2019 |
31366555 |
70 | Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report | Shuchun Li, Junjun Ma, Xizhou Hong, Minhua Zheng, Shigenori Goto, Rishu Takimoto,Takashi Kamigaki, Lu Zang | Translational Cancer Research
8(2):693-698 / 2019 |
|
69 | 4章 原発性肺癌治療の実際 薬物療法「その他の免疫療法」 | 後藤重則 | 呼吸器疾患
診断治療アプローチ 3;4章 230-234 / 2018 |
|
68 | がん免疫療法の新展開 ー 「知らない」ではすまない今のトレンド【がん免疫療法の分類と作用機序】 免疫細胞療法とは何か | 後藤重則、神垣隆、瀧澤憲 | 臨床婦人科産科
第72巻 第6号 / 2018 |
|
67 | Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy | Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S. | Anticancer Research
38 (7) 4353-4360 / 2018 |
29970573 |
66 | Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial | Yoshiki Hirooka, Hiroki Kawashima, Eizaburo Ohno, Takuya Ishikawa, Takashi Kamigaki, Shigenori Goto, Masashi Takahara, and Hidemi Goto | Oncotarget
Dec 5;9(2):2838-2847. / 2017 |
29416816 |
65 | Prospective pilot study of adoptive immunotherapy with autologous αβT cells for five cases of advanced and/or recurrent esophageal squamous cell carcinoma | Nanami T, Shimada H,Yajima S, Oshima Y, Suzuki T, Shiratori F, Sumazaki M, Otsuka S,Kamigaki T, Goto S, Kaneko H. | Esophagus
October 2017, Volume 14, Issue 4, pp 303–308 / 2017 |
|
64 | Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma | Kanemura Y, Sumida M, Okita Y, Yoshida E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Inazawa Y, Takada A, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M | Anticancer Research
Jul;37(7):3921-3932. / 2017 |
28668896 |
63 | Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study) | Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Kodama S, Yamashita Y, Hasegawa S |
Anticancer Research
Jul;37(7):3941-3946. / 2017 |
28668898 |
62 | Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells | Ishi F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, Kato D, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Hamada Y, Nimura S, Kodama S, Hasegawa S | Anticancer Research
Jul;37(7):3933-3939. / 2017 |
28668897 |
61 | Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study | Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S | Anticancer Research
Jul;37(7):3947-3954. / 2017 |
28668899 |
60 | 免疫細胞療法の現状と今後の展開 | 神垣隆、阿曽沼元博、後藤重則 | 映像MEDICAL
Vol.49 No.4 / 2017 |
|
59 | 免疫細胞療法の現状と展望 | 後藤重則、瀧本理修、牧田香理、内藤恵子、神垣隆 | 呼吸器内科
31(4):323-330, / 2017 |
|
58 | がん免疫治療 -がん完治に向けての新たな治療法の探索- II. 各論 癌免疫細胞療法 腫瘍ライセートを用いた固形腫瘍に対する樹状細胞ワクチン療法 |
神垣隆、高原将司、照屋剛、城間寛、善本隆之、後藤重則 | 日本臨床
75巻 2号 / 2017 |
|
57 | Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. | Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, Okada N. | Mol Ther Oncolytics.
Nov 16;3:16024. / 2016 |
27909701 |
56 | Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer. | Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, Hasegawa S. | Anticancer Research
Jul;36(7):3741-6. / 2016 |
27354648 |
55 | Therapeutic Potential of Zoledronate-Activated Autologous γδT Cells in Atopic Dermatitis. | Kamigaki T,Naitoh K, Goto S. | J Investig Allergol Clin Immunol.
Oct;26(5):336-338. / 2016 |
27763869 |
54 | Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells | Naitoh K, Kamigaki T, Matsuda E, Ibe H, Okada S, Oguma E, Kinoshita Y, Takimoto R, Makita K, Ogasawara S, Goto S. | Anticancer Research
36(7):3715-3724 / 2016 |
27354645 |
53 | がん免疫治療 | 神垣隆、内藤恵子、牧田香理、瀧本理修、後藤重則 | 腎臓内科・泌尿器科
3(3):294-302 / 2016 |
|
52 | T細胞輸注療法 ~肺癌・膵癌を中心として~ | 神垣隆、後藤重則 | 書籍「がん」2016年2月
第8章 第3節 / 2016 |
|
51 | 免疫細胞療法と肺がん | 後藤重則、内藤恵子、神垣隆 | 呼吸器内科
28(6):463-468 / 2015 |
|
50 | Improvement of Impaired Immunological Status of Patients with Various Types of Advanced Cancers by Autologous Immune Cell Therapy | Kamigaki T, Ibe H, Okada S, Matsuda E, Tanaka M,Oguma E, Kinoshita Y,Ogasawara S,Ono A,Makita K,Naitoh K,Goto S. | Anticancer Research
35(8):4535-4543 / 2015 |
26168498 |
49 | これから期待される肺癌診断と治療「免疫細胞治療」 | 後藤重則、神垣隆、内藤恵子 | 呼吸器内科
26(6);421-426 / 2014 |
|
48 | 免疫細胞療法の最新動向と今後の展開 | 神垣隆、後藤重則 | 腫瘍内科
第13巻 第5号 / 2014 |
|
47 | Prospective Evaluation of Safety of Immune-cell Therapy for Patients with Various Types of Advanced Cancer. | Kamigaki T, Matsuda E, Okada S, Naitoh K, Kondo T, Ibe H, Maekawa R and Goto S. | Anticancer Research
34(8):4601-7. / 2014 |
25075106 |
46 | 食道癌に対する免疫療法の現状と展望 | 神垣隆、内藤恵子、後藤重則 | Pharma Medica
Vol32 No.7. / 2014 |
|
45 | 婦人科がんに対する免疫細胞療法の実際 | 瀧澤憲、後藤重則 | 産科と婦人科
Vol.81 No.2. / 2014 |
|
44 | Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. | Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, Kamigaki T, Goto S. | International Immunopharmacology
18(1):90-97. / 2014 |
24269583 |
43 | 免疫療法:特に肺癌に対する免疫療法の可能性 | 安元公正、宗哲哉、能勢直弘、内藤恵子、富山舞、前川隆司 | 日本臨床環境医学
第22巻 第1号 / 2013 |
|
42 | Zoledronate-pulsed dendritic cell-based anticancer vaccines. | Kamigaki T, Takahara M, Maekawa R, Goto S. | Oncolmmunology
2(9):e25636. / 2013 |
24319636 |
41 | Is the CD4/CD8 Ratio an Effective Indicator for Clinical Estimation of Adoptive Immunotherapy for Cancer Treatment? | Shindo G, Endo T, Onda M, Goto S, Miyamoto Y, Kaneko T. | Cancer Therapy
4, 1382-1390. / 2013 |
|
40 | Immunotherapy of Autologous Tumor Lysate-loaded Dendritic Cell Vaccines by a Closed-flow Electroporation System for Solid Tumors. | Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S. | Anticancer Research
33(7):2971-6. / 2013 |
23780988 |
39 | A patient with Scirrhous Stomach Cancer treated with Combination of Hyperthermotherapy and 5-Aminolevulinic acid (ALA) . | Saito M, Yano K, Kamigaki T, Goto S. | Anticancer Research
33(7):2957-63. / 2013 |
23780986 |
38 | 国際的にみたがん免疫細胞治療の研究開発の現状と展望 | 後藤重則、阿曽沼元博 | 医薬品医療機器レギュラトリーサイエンス
44(6), 458-463. / 2013 |
|
37 | Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. | Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K, Tokuda H, Yamaguchi T, Mizoo A, Setoguchi Y, Kamigaki T, Fujimoto K, Goto S. | Cancer Immunology, Immunotherapy
61:1781-1790. / 2012 |
22422103 |
36 | Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers. | Sindo G, Endo T, Onda M, Miyamoto Y, Kaneko,T and Goto S. | Cancer Immunology, Immunotherapy
60(10):1397-1403. / 2011 |
21638124 |
35 | Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. | Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N, Goto S. | Cytotherapy
13(1):92-7. / 2011 |
20831354 |
34 | Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. | Kato M, Goto S, Soma G. | Anticancer Research
30(8):3125-8. / 2010 |
20871030 |
33 | A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. | Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K. | Eur J Cardiothorac Surg
37(5):1191-7. / 2010 |
20137969 |
32 | 切除不能局所進行膵癌に対するゲムシタビンと免疫細胞療法の併用治療 | 廣岡芳樹, 伊藤彰浩, 川嶋啓揮, 原和生, 野々垣浩二, 春日井俊史, 大野栄三郎, 石川卓哉, 松原浩, 石上雅敏, 片野義明, 大宮直木, 丹羽康正, 山本晃士, 金子亨, 贄田美江, 横川潔, 後藤秀実 | 膵臓
24(5):632-4. / 2009 |
|
31 | 切除不能局所進行膵癌に対するEUS下樹状細胞局注療法 | 廣岡芳樹、伊藤彰浩、川嶋啓揮、大野栄三郎、石川卓哉、松原浩、伊藤裕也、中村陽介、中村正直、宮原良二、大宮直木、石上雅敏、片野義明、金子亨、後藤重則、後藤秀実 | 胆と膵
30: 1257-61. / 2009 |
|
30 | 患者背景および腫瘍細胞の性質による免疫細胞療法の選択、個別化 | 後藤重則、金子亨、明山燿久、藤本勝洋、伊藤克礼、佐藤志保、野口敦崇、神宮司英雅 | Biotherapy
23: 317-24. / 2009 |
|
29 | EUS下穿刺術を応用した樹状細胞注入療法 | 廣岡芳樹、伊藤彰浩、川嶋啓揮、大野栄三朗、石川卓哉、松原浩、伊藤裕也、中村正直、宮原良二、大宮直木、丹羽泰正、後藤秀美、原和生、金子亨、後藤重則 | 消化器内視鏡
21: 958-63. / 2009 |
|
28 | Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. | Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K. | Exp Hematol
37(8):956-68. / 2009 |
19409955 |
27 | A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. | Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T, Matsubara H, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Yamamoto K, Kaneko T, Nieda M, Yokokawa K, Goto H. | Pancreas
38(3):e69-74. / 2009 |
19276867 |
26 | 原発性肺癌に対する活性化自己リンパ球移入療法の経験-手術不能非小細胞肺癌での遠隔成績を中心として- | 岩井和郎、後藤重則、金子亨、加藤昭、明山燿久、藤本勝洋 | Biotherapy
23: 28-36. / 2009 |
|
25 | 化学療法・放射線療法・免疫細胞療法からなる集学治療による左肺腺癌完全寛解の1例 | 加藤昭、明山燿久、和田洋巳、池田剛司、田中佳代 | Biotherapy
22: 351-6. / 2008 |
|
24 | 下咽頭癌再発、既照射例に、少線量放射線、低用量化学療法、免疫細胞療法からなる集学治療による再発腫瘍寛解の1例 | 加藤昭 | Biotherapy
20: 613-8. / 2006 |
|
23 | A Case of Recurrent Ovarian Cancer Successfully Treated with Adoptive Immunotherapy and Lentinan. | Fujimoto K, Tomonaga M, Goto S. | Anticancer Research
26: 4015-8. / 2006 |
17195451 |
22 | The Therapeutic Potential of Immuno-cell Therapy of Cancer in Combination with Aminobisphosphonates. | Goto S, Noguchi A, Jinguji H, Takahara M. | Anticancer Research
26: 3989-96. / 2006 |
17195447 |
21 | 切除不能膵癌に、gemcitabine・少線量放射線・CD3-LAK による集学的治療が有効であった1 例 | 加藤昭、明山燿久、河合公三 | Biotherapy
20: 87-90. / 2006 |
|
20 | 免疫細胞療法の現状と問題点 | 後藤重則 | 臨床放射線
50:1276-8. / 2005 |
|
19 | 免疫細胞療法の現状:普及医療としての活性化自己リンパ球療法を中心として | 江川滉二 | BCG・BRM療法研究会会誌
28:9-13. / 2005 |
|
18 | Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. | Goto S,Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T, Fujimoto K, Tomonaga M, Egawa K. | Anticancer Research
25(6A):3741-6. / 2005 |
16302734 |
17 | Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. | Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, Miyamoto Y, Eriguchi M, Egawa K. | Anticancer Research
25(6A):3709-14. / 2005 |
16302730 |
16 | 高齢者癌の治療を語る (4名の医師による高齢者の癌治療に関してのRound Table Discussion) | 畠清彦、江川滉二、小口正彦、武藤徹一郎 | 老年医学
42; 1657-1672. / 2004 |
|
15 | 高齢者に対する免疫療法:免疫細胞療法を中心として | 江川滉二 | 老年医学
42; 1643-7. / 2004 |
|
14 | 免疫細胞療法 Immuno-cell Therapy | 後藤重則, 金子亨, 江川滉二 | 日本補完代替医療学会雑誌
1(1)85-93. / 2004 |
|
13 | A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate. | Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M, Egawa K. | Anticancer Research
24; 3303- 9. / 2004 |
15515425 |
12 | Immuno-cell therapy of cancer in Japan. | Kohji Egawa | Anticancer Research
24(5C):3321-6. / 2004 |
15515427 |
11 | Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naïve and memory CD8+T cells. | Tomiyama M, akahara M, Egawa K, Nieda M. | Anticancer Research
24(5C) 3327-33. / 2004 |
15515428 |
10 | Tumor cell-specific transcription of a murine histocompatibility class Ib Q5 gene. | Noguchi K, Kuwata E, Goto S, Egawa K. | Anticancer Research
24(5C) 3379-86. / 2004 |
15515435 |
9 | Detection of anti-HLA-F antibodies in sera from cancer cancer patients. | Noguchi K, Isogai M, Kuwata E, Noguchi A, Goto S, Egawa K. | Anticancer Research
24(5C) 3387-92. / 2004 |
15515436 |
8 | On the Safety Assurance of Cell Processing Carried out in Medical Institutions for Autologous Immuno-cell Therapy. | Kohji Egawa | HUMAN CELL
17(1) 1- 6. / 2004 |
15369131 |
7 | 特集【免疫を高める方法】健康と免疫 | 後藤重則 | 健康創造研究会誌 別冊
2(2)81-86. / 2003 |
|
6 | 特集【免疫を高める方法】医療における免疫の増強 | 金子亨 | 健康創造研究会誌 別冊
2(2)113-22. / 2003 |
|
5 | 第1特集 免疫細胞療法の躍進 概論 免疫細胞療法の現状と展望 | 江川滉二 | Bioベンチャー 別冊
1(2)16-8. / 2003 |
|
4 | 第1特集 免疫細胞療法の躍進 瀬田クリニックグループでの免疫細胞療法 | 後藤重則 | Bioベンチャー 別冊
1(2)28-31. / 2003 |
|
3 | 特集【癌の免疫学-癌免疫療法の理論と臨床-】 がんの免疫細胞療法:活性化自己リンパ球療法を中心として | 江川滉二 | 呼吸
22(12)1190-5. / 2003 |
|
2 | Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy. | Nieda M, Tomiyama M, Egawa K. | HUMAN CELL
16(4)199-204. / 2003 |
15147040 |
1 | Clinical Benefit of Non-toxic Therapy in Patients with Advanced Cancer (Opinion). | Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K. | Anticancer Research
22; 2461-4. / 2002 |
12174944 |